Transpharma International (part of the Walden Group) – a specialist in pharmaceutical freight and logistics – has entered into a strategic agreement with the Arra Group, a Polish logistics company and key link in the European pharmaceutical supply chain.

Under the agreement, Transpharma International acquires 40% of the shares of Arra Group. Through this partnership, Arra Group will benefit from global expertise to implement its growth strategy and will offer its customers even greater geographic and infrastructure coverage. The alliance makes the companies the leading operators in European overland distribution for the life sciences sector (FTL/LTL).

Transpharma International

Part of Walden and focused on providing GDP compliant freight forwarding solutions for the healthcare and life sciences industry. Transpharma International transports healthcare products worldwide with 200 owned vehicles and a strategic network of 3000 vehicles in Europe. They offer first mile transport services covering all temperature ranges for manufacturers and distributors through its multiple locations in Europe.

Arra Group

Arra Group is a logistics provider specializing in the transportation of pharmaceuticals and other products requiring controlled temperature conditions from -25°C to +25°C. The company operates on the national and international market. The services offered include the highest quality road, rail, sea, air freight and contract logistics. They operate with a fleet of 400 GDP vehicles with 400 employees from their headquarter in Głogów.

Walden Group

Founded in 1951 in France, Walden Group is a family-owned company driven by a passion to become the global provider of healthcare and supply chain solutions. Walden is today the European leader in healthcare with a presence in 13 countries, more than 6,000 employees and a turnover of 1.7 billion euros.

“Transpharma International and Arra Group have long been close partners. The impressive growth of Arra Group places the company in a very high position in the European market, connecting the entire European continent on a daily basis. This cooperation will give our life science customers access to a network of 600 GDP compliant vehicles for their first mile supply chain. This partnership will provide a unique competitive solution with high quality standards for ground transportation in Europe. ” says David Evans, CEO of Transpharma International.

“Through the strategic partnership agreement between our companies, Arra Group’s customers will enjoy all the benefits of first-class expertise in the pharmaceutical supply chain. This is a step forward in realizing Arra Group’s vision of providing services on a global scale. The family character of our companies is the basis for an effective cooperation to support the development of our customers. The shared values of both companies, Arra Group and Walden Group, put everyone – their customers, patients and employees – at the center. Now we can together implement patient-oriented supply chains,” comments Artur Ratajczak, CEO of Arra Group.